Transferability of cephalothin to the alveolar cavity in thoroughbreds.
Five Thoroughbreds were classified into 4 groups according to the administration method used for saline solution (saline), ambroxol, and cephalothin sodium (cephalothin). In group A, cephalothin was injected intravenously after oral administration of ambroxol. In group B, cephalothin was injected intravenously after oral administration of saline. Groups C and D were used as control groups. The dose of cephalothin or ambroxol was clinically administrated. Venous blood and bronchoalveolar lavage fluid (BALF) were sampled from each group. In groups A and B, cephalothin concentrations in plasma reached their maximum level 5 min after cephalothin administration and then declined over time. In plasma obtained from groups A and B, there were no significant differences in pharmacokinetic parameters (T1/2, Kel, Vd). By contrast, cephalothin concentrations in BALF reached their peak at 180 min after cephalothin administration in both groups A and B and maintained a relatively high level even after 300 min. These findings indicate that cephalothin requires a relatively long period of time to move from the blood stream to the alveolar cavity, but once transferred to the alveolar cavity, it is preserved for a long time. In groups A and B, cephalothin concentrations in BALF were approximately at the same level. However, in group A, total protein in BALF was lower at 60, 180, and 300 min than the other groups. Then, cephalothin concentration was adjusted to total protein in BALF. After adjustment to total protein in BALF, group A showed a concentration level of cephalothin approximately 1.5-fold higher than that of group B. This suggests that the transferability of cephalothin to the alveolar cavity improves as a result of the oral administration of ambroxol.
Matsuda
Y
Y
Racehorse Clinic, Japan Racing Association Ritto Training Center, Shiga, Japan.
Hobo
S
S
Naito
H
H
D000551:Ambroxol / Q000494:pharmacology; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid; D002511:Cephalosporins / Q000493:pharmacokinetics*; D002512:Cephalothin / Q000493:pharmacokinetics*; D004347:Drug Interactions; D005260:Female; D006736:Horses / Q000378:metabolism*; D008297:Male; D011650:Pulmonary Alveoli / Q000378:metabolism*
D002511:Cephalosporins; D000551:Ambroxol; D002512:Cephalothin